Key questions include:

• Are current circRNA purification strategies fundamentally overcomplicated – and where can we simplify without compromising quality?
• How do you balance purity, yield, and scalability when designing purification processes for clinical and commercial manufacturing?
• What will define a “fit-for-purpose” purification platform for circRNA as the field moves toward first-in-human and beyond?